Status:
COMPLETED
The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)
Lead Sponsor:
Chugai Pharmaceutical
Collaborating Sponsors:
Japan Lung Cancer Society
Conditions:
Non-small Cell Lung Cancer
Extensive Disease Small Cell Lung Cancer
Eligibility:
All Genders
20+ years
Brief Summary
This study is implemented in association with the study "J-TAIL-2" ; prospective multicenter observational study of atezolizumab in patients with unresectable, locally advanced or metastatic non-small...
Eligibility Criteria
Inclusion
- Inclusion/exclusion criteria of J-TAIL-2 study is to be applied.
- \<non-small cell lung cancer cohort\>
- Patients 20 years of age or older at the time of signed consent.
- Patients with unresectable, advanced and recurrent non-small cell lung cancer.
- Patients who are scheduled to start atezolizumab combination therapy in clinical practice, based on the atezolizumab package insert and the Optimal Clinical Use Guideline.
- Patients who signed informed consent form before enrolling the study. The consent from a legally acceptable representative is required for the patients with uncertain capacity of judgments.
- \<extensive disease small cell lung cancer cohort\>
- Patients 20 years of age or older at the time of signed consent.
- Patients with extensive disease small cell lung cancer.
- Patients who are scheduled to start atezolizumab combination therapy in clinical practice, based on the atezolizumab package insert and the Optimal Clinical Use Guideline.
- Patients who signed informed consent form before enrolling the study. The consent from a legally acceptable representative is required for the patients with uncertain capacity of judgments. However, the samples of dead cases can be used for the analysis of immune microenvironment of small cell lung cancer by disclosing information on this study.
Exclusion
- \<non-small cell lung cancer cohort\>
- 1\. Patients who are unsuitable for enrolment into the study by the investigator's judgment.
- \<extensive disease small cell lung cancer cohort\>
- 1\. Patients who are unsuitable for enrolment into the study by the investigator's judgment.
Key Trial Info
Start Date :
April 7 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 3 2023
Estimated Enrollment :
470 Patients enrolled
Trial Details
Trial ID
NCT04818983
Start Date
April 7 2021
End Date
February 3 2023
Last Update
April 2 2024
Active Locations (95)
Enter a location and click search to find clinical trials sorted by distance.
1
Hyogo Cancer Center
Akashi, Japan
2
Asahikawa Medical University Hospital
Asahikawa, Japan
3
National Hospital Organization Asahikawa Medical Center
Asahikawa, Japan
4
Juntendo University Hospital
Bunkyō City, Japan